Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

See, Kay Choong

doi:10.3390/vaccines11121809

Cited by 3 publications

(1 citation statement)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, health systems must ensure that RSV vaccines are available in terms of affordability and accessibility, particularly in low- and middle-income countries. The provision of further trial data and comprehensive post-market surveillance of RSV vaccines will help to build confidence in long-term efficacy and safety ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

Characterisation of RSV infections in children without chronic diseases aged 0–36 months during the post-COVID-19 winter season 2022/2023

Meier,

Riepl,

Voitl

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

BackgroundRespiratory syncytial virus (RSV) is one of the leading causes of hospitalisation, morbidity, and mortality due to respiratory infection in the first years of life. This longitudinal prospective study outlines the 2022/23 season's viral patterns in Austria after the epidemiological changes determined by public health measures. We aimed to highlight differences within the RSV subtypes and genotypes in 0–36-month-old children without chronic diseases in the outpatient setting.MethodsFrom November 2022 to March 2023 children younger than 36 months admitted to Vienna's largest paediatric primary healthcare centre with an acute respiratory infection were enrolled in this study. Nasal swabs and multiplex PCR panels detected 20 viruses including RSV subtypes and genotypes. Clinical presentation, features, and treatment of the participants were documented and analysed using the Modified Tal Score (MTS). Patients were scheduled for a telemedical follow-up one week after the initial appointment. Analysis was done using descriptive statistics, including Cramér V and binominal logarithmic regression.ResultsAmong the 345 samples from 329 children, RSV was the most common virus (31.9%), followed by influenza (17.5%) and rhinovirus infections (20.58%). Of the RSV positive samples, only 13 cases were RSV subtype A (11.8%), whereas 97 were of subtype B (87.3%); ON1 and BA9 were the only detectable RSV genotypes (ON1: BA9 = 1:9.25). RSV was the main predictor of hospitalisation (OR: 7.5, 95% CI: (1.46–38.40), and age had a significant but smaller effect (OR: 0.89, 95% CI: (0.81–0.99). Almost all patients' clinical status improved within the first days.ConclusionRSV cases showed a rapid onset in late November 2022, and subtype B was predominant throughout the season. RSV infection was associated with higher hospitalisation rates, even after excluding high-risk patients (preterm and severe chronic diseases population).Further testing in the upcoming winter seasons will improve our knowledge of the dominant subtype and its association with disease severity, especially with the development of novel RSV vaccine candidates.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterisation of RSV infections in children without chronic diseases aged 0–36 months during the post-COVID-19 winter season 2022/2023

Meier,

Riepl,

Voitl

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase

Bonneux,

Shareef,

Tcherniuk

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

Management of vaccinations in patients with non‐Hodgkin lymphoma

Merli,

Costantini,

Tafuri

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryVaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non‐Hodgkin lymphomas (NHLs). The COVID‐19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life‐threatening SARS‐CoV‐2‐related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine‐induced immune responses after anti‐CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID‐19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team‐based recommendations for the management of vaccines in this specific group of patients.

show abstract

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

Cited by 3 publications

References 96 publications

Characterisation of RSV infections in children without chronic diseases aged 0–36 months during the post-COVID-19 winter season 2022/2023

Characterisation of RSV infections in children without chronic diseases aged 0–36 months during the post-COVID-19 winter season 2022/2023

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase

Management of vaccinations in patients with non‐Hodgkin lymphoma

Contact Info

Product

Resources

About